[Current status and future perspectives of the Glivec Registration System established by JSCH/JSH-TARGET].
Kizaki
Masahiro
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D016208:Databases, Factual; D005260:Female; D016044:Fusion Proteins, bcr-abl; D006405:Hematology; D006801:Humans; D000068877:Imatinib Mesylate; D007564:Japan; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000235:genetics; D011743:Pyrimidines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012955:Societies, Medical
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl